FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Breaking News
07/22/2021
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
|
|
07/12/2021
Gut Microbes Signal Response to Immune Therapy in Melanoma
(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
|
|
06/30/2021
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
|
|
06/15/2021
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
|
|
06/04/2021
Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
|
|
06/04/2021
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
June 04, 2021 09:08 ET | Source: Iovance Biotherapeutics, Inc. 86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune…
|
05/28/2021
How Tennis Star Naomi Osaka is Helping People of Color Protect Their Skin
We’re proud to partner with Mediaplanet on the recently published Skin Health campaign, out today! Skin diseases affect as many…
|
05/21/2021
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
|
|
04/15/2021
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
|
|
04/14/2021
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
|
|
Recent Posts
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024
Managing Melanoma During the Holiday Season
Dec. 05, 2024
Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship
Dec. 03, 2024